To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
Completed
GlaxoSmithKline
Phase 2
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity,
PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects
with primary insomnia
Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG
nights, study drug administration and noise model is conducted on second night.
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
Completed
GlaxoSmithKline
Phase 1
Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7
days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and
cognition function tests.
Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug
Completed
GlaxoSmithKline
Phase 1
The purpose of this study is to define the absorption, breakdown and excretion of a single
dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration
in blood, urine and faeces over a 7-10 day period. "Radiolabelled" means that the test drug
has a radioactive component to help us track the drug. The safety and tolerability of the
test drug will also be assessed.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
